1620 Investment Advisors’s United Therapeutics UTHR Stock Holding History

1620 Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$193K	Sell	356 -25	-7%	-$14.1K	0.12%	184
2026 Q1	$226K	Sell	381 -3	-0.8%	-$1.49K	0.15%	145
2025 Q4	$187K	Buy	384 +1	+0.3%	+$466	0.12%	164
2025 Q3	$161K	Sell	383 -3	-0.8%	-$1.01K	0.11%	174
2025 Q2	$111K	Sell	386 -2	-0.5%	-$598	0.08%	215
2025 Q1	$120K	Buy	388 +5	+1%	+$1.71K	0.09%	191
2024 Q4	$135K	Sell	383 -20	-5%	-$7.35K	0.1%	184
2024 Q3	$144K	Buy	403 +17	+4%	+$5.74K	0.1%	180
2024 Q2	$123K	Buy	+386	New	+$102K	0.09%	196

Other funds holding UTHR

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

1620 Investment Advisors's UTHR Position: Q2 2026 in Review

1620 Investment Advisors reduced its United Therapeutics (UTHR) stake by 6.6% in Q2 2026, selling an estimated $14.1K and leaving 356 shares worth $193K. The position accounts for 0.12% of the portfolio, ranked #184.

1620 Investment Advisors first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $226K in Q1 2026. 219 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

1620 Investment Advisors held 356 shares of United Therapeutics worth $193K as of Q2 2026.
1620 Investment Advisors sold 25 United Therapeutics shares in Q2 2026, an estimated $14.1K.
United Therapeutics made up 0.12% of 1620 Investment Advisors's portfolio in Q2 2026, its #184 holding.
1620 Investment Advisors first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
1620 Investment Advisors's United Therapeutics position peaked at $226K in Q1 2026.
219 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.